Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enanta Pharmaceuticals

5.63
+0.05000.90%
Pre-market: 5.910.2800+4.97%08:00 EDT
Volume:110.34K
Turnover:621.79K
Market Cap:120.10M
PE:-1.14
High:5.80
Open:5.56
Low:5.56
Close:5.58
Loading ...

BRIEF-Enanta Pharmaceuticals Q1 Revenue USD 16.959 Million

Reuters
·
11 Feb

Enanta Pharmaceuticals Q1 Operating Income USD -23.543 Million

THOMSON REUTERS
·
11 Feb

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Business Wire
·
11 Feb

Enanta Pharmaceuticals Inc expected to post a loss of $1.35 a share - Earnings Preview

Reuters
·
08 Feb

Enanta Pharmaceuticals Inc expected to post a loss of $1.35 a share - Earnings Preview

Reuters
·
04 Feb

Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?

Zacks
·
23 Jan

U.S. RESEARCH ROUNDUP-BTCS, Gevo, ServiceNow

Reuters
·
24 Dec 2024

HC Wainwright Adjusts Price Target on Enanta Pharmaceuticals to $18 From $27, Maintains Buy Rating

MT Newswires Live
·
24 Dec 2024

Enanta to appeal ruling related to ‘953 patent infringement lawsuit

TIPRANKS
·
24 Dec 2024

Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer

Dow Jones
·
24 Dec 2024

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

THOMSON REUTERS
·
24 Dec 2024

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Business Wire
·
24 Dec 2024

Enanta Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
24 Dec 2024

Promising Virology Outcomes Boost Buy Rating for Enanta Pharmaceuticals Despite Symptom Assessment Concerns

TIPRANKS
·
24 Dec 2024

Enanta price target lowered to $18 from $27 at H.C. Wainwright

TIPRANKS
·
24 Dec 2024

Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?

Zacks
·
23 Dec 2024

Enanta Pharmaceuticals: Undervalued Potential Beyond Hepatitis C – Buy Recommendation by Roy Buchanan

TIPRANKS
·
13 Dec 2024

Evercore ISI Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA)

TIPRANKS
·
11 Dec 2024

Enanta Pharmaceuticals’ RSV Platform Advances: Buy Rating Affirmed on Promising Clinical Data

TIPRANKS
·
10 Dec 2024

Enanta Pharma Reports Positive Phase 2 Results for Zelicapavir as Treatment of Respiratory Syncytial Virus

MT Newswires Live
·
09 Dec 2024